Lacosamida asociada a bloqueo de alto grado en un paciente con neuralgia del trigémino

Marín-Gracia, M; Cantero-Lozano, Daniel; Garcés-Antón, E; López-Bravo, A.; Garrido-Fernández, A.; Navarro-Pérez, María Pilar; Santos-Lasaosa, S; Garcés-Redondo, Moisés

doi:10.33588/rn.6606.2017447

Cited by 7 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, we found a death report for one of the excluded patients due to lack of follow‐up, and although this was a 95‐year‐old woman with multiple ongoing treatments, including carbamazepine, her death was attributed to an AVB occurring 5 months after lacosamide initiation. This rare but serious complication has been reported before with lacosamide, 19 so awareness is necessary regarding its use, with previous electrocardiography obtention and close monitoring being mandatory.…”

Section: Discussionmentioning

confidence: 89%

Oral lacosamide for the treatment of refractory trigeminal neuralgia: A retrospective analysis of 86 cases

et al. 2023

View full text Add to dashboard Cite

Background and Objectives: First-line treatment for trigeminal neuralgia (TN) is limited to carbamazepine and oxcarbazepine, and in refractory cases, alternatives are scarce.Lacosamide has been suggested as a valid option. In this study, we describe a series of patients who received oral lacosamide as treatment for TN after first-line drug failure. Methods:In this retrospective descriptive cohort study, we included patients with refractory TN who attended a tertiary center between 2015 and 2021 and were prescribed oral lacosamide after first-line treatment failure. The primary endpoints were pain relief and adverse effects. We secondarily analyzed clinical outcomes and compared responders versus nonresponders in the search for potential predictors of response.Results: Eighty-six patients were included (mean age: 62 [SD 15.6] years; 54/86 [63%] female). The TN etiology was secondary in 16/86 (19%) patients. Concomitant continuous pain was present in 29/86 (34%) patients. The mean number of previous treatments was 2.7 [SD 1.5]. Pain relief was achieved in 57/86 (66%) cases, with 28/86 (33%) patients presenting adverse effects, all of which were mild. No statistically significant differences were observed between responders and nonresponders, but subtle clinical differences suggested potential predictors of response. Conclusion:Lacosamide may be an effective and relatively safe treatment for refractory pain in TN patients after first-line treatment failure.

show abstract

Section: Discussionmentioning

confidence: 89%

Oral lacosamide for the treatment of refractory trigeminal neuralgia: A retrospective analysis of 86 cases

et al. 2023

View full text Add to dashboard Cite

show abstract

Lacosamide

2018

Reactions Weekly

View full text Add to dashboard Cite

Effects of palmatine on BDNF/TrkB-mediated trigeminal neuralgia

Liu

Yin

et al. 2020

Sci Rep

View full text Add to dashboard Cite

Trigeminal neuralgia (TN), a sudden, needle-like pain in the distribution area of the trigeminal nerve, can seriously affect the physical and mental health of patients. In chronic pain conditions including TN, increased levels of brain-derived neurotrophic factor (BDNF) may enhance pain transmission. This study compares the effect of palmatine administration on the expression of BDNF and its receptor TrkB (tropomyosin receptor kinase B) in trigeminal ganglion cells of Sprague-Dawley rats in a shamversus TN model group. Within 14 days of surgery, the mechanical allodynia threshold of the TN group was significantly lower than that of the sham group, while the TN + palmatine group had a higher mechanical pain sensitivity threshold than the TN group (p < 0.05). Real-time quantitative PCR, immunohistochemistry, and immunofluorescence showed that BDNF and TrkB expression in the TN group was higher than that in the sham group, while palmatine treatment could reverse these changes. Western blotting showed that palmatine treatment could reduce the elevated phosphorylation of extracellular signal-regulated kinases 1/2 (ERK1/2) in TN rats. Thus, the BDNF/TrkB pathway may be involved in the pain transmission process of TN, and palmatine treatment may reduce pain transmission by inhibiting the BDNF/TrkB pathway and suppressing ERK1/2 phosphorylation.

show abstract

Lacosamida asociada a bloqueo de alto grado en un paciente con neuralgia del trigémino

Cited by 7 publications

References 0 publications

Oral lacosamide for the treatment of refractory trigeminal neuralgia: A retrospective analysis of 86 cases

Oral lacosamide for the treatment of refractory trigeminal neuralgia: A retrospective analysis of 86 cases

Lacosamide

Effects of palmatine on BDNF/TrkB-mediated trigeminal neuralgia

Contact Info

Product

Resources

About